NCT06996249 2026-03-03
DuTOC
Dutch Society of Physicians for Pulmonology and Tuberculosis
Recruiting
Clinical Trials
31 trialsNCT01946100 2025-11-20
Treatment of Multifocal Lung Adenocarcinoma
Mayo Clinic
Phase NA Terminated
NCT02664935 2025-05-21
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Active not recruiting
NCT04263090 2024-05-09
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT04401059 2023-12-27
SELECT-2
Hangzhou Normal University
Phase 4 Recruiting
NCT03215810 2023-07-24
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02183870 2022-06-16
EUCROSS
University of Cologne
Phase 2 Completed
NCT02498860 2021-08-06
APICAL
Chonnam National University Hospital
Phase 2 Completed
NCT02410603 2021-07-21
Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
Mayo Clinic
Completed
NCT00137839 2019-12-17
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00563784 2019-11-20
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02466568 2019-09-09
Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Withdrawn
NCT01433172 2019-08-06
Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01837329 2019-07-19
Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer
University of Rochester
Phase 1 Completed
NCT02271906 2019-04-30
The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02341170 2019-04-17
HIPPO-S
Universitätsmedizin Mannheim
Phase NA Withdrawn
NCT01662635 2019-01-09
ALK
Instituto Nacional de Cancerologia de Mexico
Completed
NCT02370303 2018-03-21
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
Mayo Clinic
Completed
NCT01511081 2017-12-07
Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02422628 2016-12-14
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC
National Taiwan University Hospital
Unknown
NCT02951637 2016-11-01
Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial
Shanghai Chest Hospital
Phase 2 Unknown
NCT00832715 2016-07-20
Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02738684 2016-04-14
A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test
Southwest Hospital, China
Unknown
NCT00940069 2016-02-22
TPEIAL
Hunan Province Tumor Hospital
Phase 2 Completed
NCT00716456 2015-04-30
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01565538 2014-09-15
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
Sun Yat-sen University
Phase 2 Completed
NCT00132704 2014-07-24
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Memorial Sloan Kettering Cancer Center
Completed
NCT01637376 2014-01-15
Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer
University of Arkansas
Phase 1 Withdrawn
NCT01871480 2013-12-30
CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer
Kunming Medical University
Phase 2 Terminated
NCT00430261 2010-10-06
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
Swedish Medical Center
Phase 2 Completed
NCT00908336 2009-05-25
Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen
Hospital Arnau de Vilanova
Phase 2 Unknown